LYSARC,
Academic partner
of Lymphoma
Clinical Research

LYSA’s RELEVANCE Trial in the Media

20 June 2018,

Return on the presentation of Franck Morschhauser, from Claude Huriez Hospital (Lille, France), president of the LYSA scientific committee, on the interim results obtained for the phase III clinical trial RELEVANCE conducted by LYSARC.

Please, discover the press release on this study, published on the website of ASH and the video made by ecancer!


Reference : Franck Morschhauser et al. RELEVANCE : PHASE III EFFICACY AND SAFETY STUDY OF LENALIDOMIDE PLUS RITUXIMAB (R2) VERSUS RITUXIMAB PLUS CHEMOTHERAPY, FOLLOWED BY RITUXIMAB, IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA